Option Care Health (OPCH)


Market Price (11/22/2026): $31.58 | Market Cap: $4.7 BilSector: Health Care | Industry: Health Care Facilities

Option Care Health (OPCH)


Market Price (11/22/2026): $31.58
Market Cap: $4.7 Bil
Sector: Health Care
Industry: Health Care Facilities

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Attractive yield
FCF Yield is 6.0%

Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Remote Patient Monitoring, Oncology Treatments, Show more.

Weak multi-year price returns
3Y Excs Rtn is -57%

Key risks
OPCH key risks include [1] persistent margin pressure from reduced reimbursement rates by third-party payers and [2] an anticipated negative impact on 2025 gross profit due to a key supplier's pricing change on a specific therapy.

0 Attractive yield
FCF Yield is 6.0%
1 Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Remote Patient Monitoring, Oncology Treatments, Show more.
2 Weak multi-year price returns
3Y Excs Rtn is -57%
3 Key risks
OPCH key risks include [1] persistent margin pressure from reduced reimbursement rates by third-party payers and [2] an anticipated negative impact on 2025 gross profit due to a key supplier's pricing change on a specific therapy.

OPCH in ETFs

Weight = OPCH's share of each fund

VTI0.01%
ITOT0.01%
IWM0.18%
IJH0.14%
VB0.06%
IHF0.62%
IWO0.29%
MDYG0.28%
+16 more covered ETFs

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/20/2026

Up 63.2% from its May 15 low to Oct 29 (S&P 500 up 4.6%)
The stock's run was driven by its Q2 2026 earnings beating estimates, along with days of significant gains without company-specific news. The company reported strong Q2 results on July 29, and major increases occurred on May 20 and October 6 without company headlines.

Nov 4: down 0.4% on its earnings report (S&P 500 up 1.7%)
The stock traded flat on its Q3 2026 earnings report, despite the company announcing figures that surpassed estimates. This muted reaction occurred as the overall market rose significantly, suggesting other factors weighed on the stock.

Show more
Prices as of 11/20/2026

Up 63.2% from its May 15 low to Oct 29 (S&P 500 up 4.6%)
The stock's run was driven by its Q2 2026 earnings beating estimates, along with days of significant gains without company-specific news. The company reported strong Q2 results on July 29, and major increases occurred on May 20 and October 6 without company headlines.

Nov 4: down 0.4% on its earnings report (S&P 500 up 1.7%)
The stock traded flat on its Q3 2026 earnings report, despite the company announcing figures that surpassed estimates. This muted reaction occurred as the overall market rose significantly, suggesting other factors weighed on the stock.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 37.2% change in OPCH stock from 7/31/2026 to 11/21/2026 was primarily driven by a 30.8% change in the company's P/E Multiple.
(LTM values as of)731202611212026Change
Stock Price ($)23.0331.5937.2%
Change Contribution By: 
Total Revenues ($ Mil)5,6945,7521.0%
Net Income Margin (%)3.7%3.7%1.6%
P/E Multiple16.822.030.8%
Shares Outstanding (Mil)1531502.1%
Cumulative Contribution37.2%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/21/2026
ReturnCorrelation
OPCH37.2% 
Market (SPY)-7.4%11.9%
Sector (XLV)9.5%4.7%

Fundamental Drivers

The 55.4% change in OPCH stock from 4/30/2026 to 11/21/2026 was primarily driven by a 42.4% change in the company's P/E Multiple.
(LTM values as of)430202611212026Change
Stock Price ($)20.3331.5955.4%
Change Contribution By: 
Total Revenues ($ Mil)5,6675,7521.5%
Net Income Margin (%)3.6%3.7%2.8%
P/E Multiple15.422.042.4%
Shares Outstanding (Mil)1571504.6%
Cumulative Contribution55.4%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/21/2026
ReturnCorrelation
OPCH55.4% 
Market (SPY)-3.5%-2.2%
Sector (XLV)22.4%9.4%

Fundamental Drivers

The 21.4% change in OPCH stock from 10/31/2025 to 11/21/2026 was primarily driven by a 9.2% change in the company's P/E Multiple.
(LTM values as of)1031202511212026Change
Stock Price ($)26.0331.5921.4%
Change Contribution By: 
Total Revenues ($ Mil)5,5305,7524.0%
Net Income Margin (%)3.8%3.7%-1.1%
P/E Multiple20.122.09.2%
Shares Outstanding (Mil)1621508.0%
Cumulative Contribution21.4%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/21/2026
ReturnCorrelation
OPCH21.4% 
Market (SPY)2.2%0.7%
Sector (XLV)24.9%10.5%

Fundamental Drivers

The 13.9% change in OPCH stock from 10/31/2023 to 11/21/2026 was primarily driven by a 36.8% change in the company's Total Revenues ($ Mil).
(LTM values as of)1031202311212026Change
Stock Price ($)27.7331.5913.9%
Change Contribution By: 
Total Revenues ($ Mil)4,2055,75236.8%
Net Income Margin (%)6.1%3.7%-38.9%
P/E Multiple19.322.014.2%
Shares Outstanding (Mil)17915019.4%
Cumulative Contribution13.9%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/21/2026
ReturnCorrelation
OPCH13.9% 
Market (SPY)71.0%13.6%
Sector (XLV)49.6%22.3%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
OPCH Return82%6%12%-31%37%-1%102%
Peers Return11%-21%56%16%29%15%134%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
OPCH Win Rate58%50%67%42%50%55% 
Peers Win Rate46%38%44%52%58%52% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
OPCH Max Drawdown-22%-66%-25%-37%-26%-47% 
Peers Max Drawdown-22%-38%-29%-26%-37%-29% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: CVS, UNH, AVAH, ADUS.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/20/2026 (YTD)

How Low Can It Go

EventOPCHS&P 500
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-19.2%-9.5%
  % Gain to Breakeven23.7%10.5%
  Time to Breakeven55 days24 days
2022 Inflation Shock & Fed Tightening
  % Loss-65.6%-24.5%
  % Gain to Breakeven190.3%32.4%
  Time to Breakeven60 days427 days
2020 COVID-19 Crash
  % Loss-65.5%-33.7%
  % Gain to Breakeven189.6%50.9%
  Time to Breakeven307 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-16.6%-19.2%
  % Gain to Breakeven19.9%23.8%
  Time to Breakeven11 days105 days
2016-2017 Trump Reflation Bond Selloff
  % Loss-65.1%-3.7%
  % Gain to Breakeven186.3%3.9%
  Time to Breakeven188 days6 days
2015-2016 China Devaluation / Global Growth Scare
  % Loss-17.9%-12.2%
  % Gain to Breakeven21.9%13.9%
  Time to Breakeven7 days62 days

Compare to CVS, UNH, AVAH, ADUS

In The Past

Option Care Health's stock fell -5.1% during the 2025 US Tariff Shock. Such a loss loss requires a 5.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventOPCHS&P 500
2022 Inflation Shock & Fed Tightening
  % Loss-65.6%-24.5%
  % Gain to Breakeven190.3%32.4%
  Time to Breakeven60 days427 days
2020 COVID-19 Crash
  % Loss-65.5%-33.7%
  % Gain to Breakeven189.6%50.9%
  Time to Breakeven307 days140 days
2016-2017 Trump Reflation Bond Selloff
  % Loss-65.1%-3.7%
  % Gain to Breakeven186.3%3.9%
  Time to Breakeven188 days6 days
2014-2016 Oil Price Collapse
  % Loss-84.9%-6.8%
  % Gain to Breakeven560.9%7.3%
  Time to Breakeven2388 days15 days
2011 US Debt Ceiling Crisis & European Contagion
  % Loss-25.9%-17.9%
  % Gain to Breakeven35.0%21.8%
  Time to Breakeven210 days123 days
2010 Eurozone Sovereign Debt Crisis / Flash Crash
  % Loss-54.8%-15.4%
  % Gain to Breakeven121.4%18.2%
  Time to Breakeven796 days125 days
2008-2009 Global Financial Crisis
  % Loss-84.0%-53.4%
  % Gain to Breakeven525.7%114.4%
  Time to Breakeven355 days1085 days

Compare to CVS, UNH, AVAH, ADUS

In The Past

Option Care Health's stock fell -5.1% during the 2025 US Tariff Shock. Such a loss loss requires a 5.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Option Care Health (OPCH)

Option Care Health (OPCH) is a prominent healthcare company specializing in the provision of home and alternate site infusion services throughout the United States. The company's core business involves delivering critical medical therapies directly to patients' residences or other non-hospital settings, allowing individuals with a diverse array of acute and chronic conditions to receive specialized care outside of traditional inpatient facilities.

OPCH's extensive service portfolio covers numerous therapeutic areas. This includes anti-infective therapies, home infusion services for heart failure, and nutritional support for conditions such as stroke, cancer, and gastrointestinal diseases. The company also provides immunoglobulin infusion therapies for immune deficiencies, treatments for chronic inflammatory disorders like Crohn's disease and rheumatoid arthritis, and management for neurological conditions such as amyotrophic lateral sclerosis and duchenne muscular dystrophy. Additionally, Option Care Health offers therapies for bleeding disorders, high-risk pregnancies, pain management, chemotherapy, and respiratory ailments, often integrated with professional nursing support.

AI Analysis | Feedback

1. It's like a 'Mayo Clinic for infusion therapies,' but the treatments and expert nurses come directly to your home instead of you going to a central facility.

2. Think of it as 'Carvana for specialized medical infusions,' where Option Care Health brings complex, hospital-level treatments and expert nursing care directly to your home, bypassing traditional clinics.

AI Analysis | Feedback

  • Anti-infective Infusion Therapies: Provides home infusion services for treating various infections.
  • Heart Failure Infusion Therapies: Offers home infusion services specifically designed to treat heart failures.
  • Nutrition Support Services: Delivers home parenteral and enteral nutrition for acute and chronic conditions like stroke, cancer, and gastrointestinal diseases.
  • Immunoglobulin Infusion Therapies: Administers treatments for patients suffering from immune deficiencies.
  • Chronic Inflammatory Disorder Treatments: Supplies therapies for conditions such as Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis.
  • Neurological Disorder Therapies: Manages the progression of neurological disorders like amyotrophic lateral sclerosis and duchenne muscular dystrophy through infusion.
  • Bleeding Disorder Therapies: Provides infusion therapies tailored for various bleeding disorders.
  • High-Risk Pregnancy Therapies: Offers essential therapies to support women through high-risk pregnancies.
  • Other Specialized Infusion Therapies: Includes treatments for pain management, chemotherapy, and respiratory medications for various conditions.
  • Nursing Services: Provides professional nursing support alongside infusion therapies.

AI Analysis | Feedback

Option Care Health (OPCH) primarily sells its home and alternate site infusion services to **individuals** (patients) in the United States. Based on the therapies and conditions mentioned in the company description, its customer base can be categorized as follows:

  1. Patients with Complex and Chronic Conditions: This category includes individuals requiring ongoing infusion therapies for long-term management of conditions such as heart failure, neurological disorders (e.g., amyotrophic lateral sclerosis, duchenne muscular dystrophy), bleeding disorders, chronic inflammatory disorders (e.g., Crohn's disease, rheumatoid arthritis), and those needing home parenteral or enteral nutrition support for various acute and chronic conditions.

  2. Patients Requiring Anti-infective and Acute Care Therapies: This segment comprises individuals receiving anti-infective therapies, as well as those needing infusion services for pain management, chemotherapy for cancer treatment, and respiratory medications, often for more acute or specific treatment courses.

  3. Patients with Immune Deficiencies and High-Risk Pregnancy Needs: This category serves specialized patient populations, specifically those requiring immunoglobulin infusion therapies for the treatment of immune deficiencies and women needing specialized therapies to manage high-risk pregnancies.

AI Analysis | Feedback

  • McKesson Corporation (MCK)
  • Cencora (COR)
  • Cardinal Health, Inc. (CAH)

AI Analysis | Feedback

John C. Rademacher, President and Chief Executive Officer

John C. Rademacher was appointed CEO of Option Care Health in January 2018, having previously served as interim CEO since August 2017. From 2015 to 2018, he was the company's Chief Operating Officer. Prior to joining Option Care Health, Mr. Rademacher held various executive-level positions at leading healthcare companies. These roles included President of Ambulatory Care (2012-2014) and President of Nuclear & Pharmacy Services (2007-2012) at Cardinal Health, Inc., a publicly-traded multinational healthcare services company. He also served as President of CareAllies and Chief Operating Officer for the CIGNA Behavioral Health business at Cigna Corporation, where he was responsible for developing and delivering care management and population health programs.

Meenal Sethna, Chief Financial Officer

Meenal Sethna assumed the role of Chief Financial Officer for Option Care Health on October 1, 2025. Before joining Option Care Health, she served as CFO of Littelfuse, an industrial technology manufacturing company. Ms. Sethna has also held leadership positions at Illinois Tool Works, a specialized industrial equipment and consumables manufacturer, and has worked at Motorola and Baxter International.

Luke Whitworth, Chief Operating Officer

Luke Whitworth brings extensive healthcare and leadership experience to Option Care Health. He spent nearly fifteen years at Cardinal Health, where he gained a track record of accomplishment across Finance, Mergers and Acquisitions, Integration, Sales, and General Management. At Cardinal Health, he served as the finance executive responsible for building a multi-billion dollar post-acute business spanning distribution, services, and technology. He also held sales and general management responsibility for Home Healthcare Solutions, driving significant growth, customer acquisition, and efficiency.

Collin Smyser, General Counsel and Corporate Secretary

Collin Smyser serves as the General Counsel and Corporate Secretary for Option Care Health. Before joining the company, Mr. Smyser was the Vice President, Deputy General Counsel for Elanco Animal Health Incorporated. In that role, he served as Elanco's chief corporate governance, securities, and corporate transactions attorney.

Michael Bavaro, Chief Human Resources Officer and Chief Diversity Officer

Michael Bavaro serves Option Care Health as the Chief Human Resources Officer and Chief Diversity Officer, with over 20 years of human resource leadership experience. Prior to joining Option Care Health in 2016, Mr. Bavaro was a divisional Vice President at Blue Cross Blue Shield of IL, TX, NM, MT & OK. He was responsible for all talent acquisition and workforce strategies at Blue Cross Blue Shield and served as the company's interim Diversity and Inclusion Officer. Mr. Bavaro also held senior HR roles at Career Education Corporation and United Airlines.

AI Analysis | Feedback

The key risks to Option Care Health (OPCH) include:

  1. Biosimilar Competition and Margin Compression: The introduction of biosimilars for key high-margin drugs, such as Stelara, is significantly impacting Option Care Health's gross profit and overall margins. This loss of exclusivity for branded drugs and a shift in product mix toward lower-margin therapies, along with rising drug costs, is creating a substantial financial headwind for the company, with projected impacts of tens of millions of dollars on gross profit.
  2. Reimbursement Pressures and Dependence on Third-Party Payers: Option Care Health is highly dependent on third-party payers, including managed care organizations and government programs like Medicare and Medicaid, for a significant portion of its revenue. Changes in reimbursement policies and rates, including federal reimbursement pressures and potential price cuts, can directly reduce the company's revenue and profitability.
  3. Labor Shortages and Inability to Attract and Retain Skilled Clinicians: The healthcare sector is experiencing ongoing workforce shortages, particularly for skilled clinicians such as nurses, who are essential for Option Care Health's home and alternate site infusion services. An inability to attract and retain qualified staff could hinder the company's ability to provide services, support growth, and may lead to increased operational costs.

AI Analysis | Feedback

The primary emerging threat to Option Care Health stems from the ongoing advancements in pharmaceutical development, specifically the increasing prevalence and adoption of alternative, non-infusion drug delivery methods. Many conditions currently requiring intravenous (IV) infusion therapies, which form the core of Option Care Health's services, are seeing the emergence of equally effective and more convenient oral medications or self-administered subcutaneous injectable therapies. As these non-infusion alternatives gain market share, the demand for traditional infusion services could diminish for a significant portion of the conditions Option Care Health treats, directly impacting its business model and patient volumes.

AI Analysis | Feedback

For Option Care Health (symbol: OPCH), the addressable markets for its main products and services in the United States are as follows:

  • Overall U.S. Home Infusion Therapy Market: The U.S. home infusion therapy market was valued at approximately USD 19.65 billion in 2024 and is projected to grow to about USD 38.02 billion by 2032. Other estimates for the U.S. market in 2024 range from USD 20.42 billion to USD 21.3 billion, with projections reaching USD 39.96 billion to USD 41.0 billion by 2033. Option Care Health itself estimates the home infusion market at USD 17 billion to USD 18 billion.
  • Anti-infective Therapies (Home Infusion): This segment constituted a significant portion of the U.S. home infusion therapy market, holding a share of approximately 26.94% in 2024. Another source indicates it held a 27% share in 2025.
  • Immunoglobulin Infusion Therapies (IVIG and SCIG) in the U.S.:
    • The U.S. Intravenous Immunoglobulin (IVIG) market was valued at USD 7.02 billion in 2024 and is projected to reach USD 14.03 billion by 2033. Another estimate places the U.S. IVIG market at USD 7.27 billion in 2024, projected to reach USD 14.42 billion by 2033. Within the U.S. home infusion therapy market, immunoglobulin therapy was the largest indication segment, accounting for 31.2% market share in 2024.
    • The U.S. Subcutaneous Immunoglobulin (SCIG) market size was valued at USD 3.86 billion in 2024 and is expected to grow to USD 9.46 billion by 2034.
  • Home Parenteral and Enteral Nutrition Support Services (U.S.):
    • The U.S. enteral nutrition products market was valued at USD 2.84 billion in 2023 and is projected to grow to USD 4.86 billion by 2032. Within the U.S. home infusion therapy market, the enteral nutrition segment was valued at USD 3.5 billion in 2024.
    • The U.S. parenteral nutrition market generated a revenue of USD 2.57 billion in 2023 and is expected to reach USD 3.84 billion by 2030. The broader North American homecare clinical nutrition market (which includes both enteral and parenteral) was valued at USD 7.62 billion in 2025.
  • Chemotherapy (Home Infusion) in the U.S.: The chemotherapy at home services market in the United States is expected to reach a projected revenue of approximately USD 1.06 billion by 2030. Chemotherapy infusion is identified as a rapidly growing application within the home infusion market.
  • Pain Management (Infusion Therapies) in the U.S.: The U.S. pain management devices market, which includes analgesic infusion pumps, generated USD 2.97 billion in revenue in 2024 and is expected to reach USD 4.93 billion by 2030.
  • Treatments for Neurological Disorders (Home Infusion) in the U.S.: The outpatient infusion market (including at home) for neurological conditions is expanding and is projected to reach nearly USD 38.0 billion by 2034.

AI Analysis | Feedback

Here are 3-5 expected drivers of future revenue growth for Option Care Health (OPCH) over the next 2-3 years:
  1. Expansion of Therapy Portfolio: Option Care Health is strategically broadening its therapy portfolio, with a significant focus on new treatments for acute and chronic care categories. This includes substantial investments in specialty areas such as oncology services, particularly PD-1 drugs, and neurology. The company aims to advance specialized therapies through collaborations.
  2. Geographic and Site of Care Expansion: The company is actively pursuing growth by expanding its physical infrastructure and increasing patient access. In the first quarter of 2025, Option Care Health opened three new infusion clinics. The company has also been expanding its infusion suites, adding over 80 infusion chairs and implementing more than 25 advanced practitioner-capable locations. This expansion also includes new pharmacies and infusion suites in various locations.
  3. Strategic Mergers and Acquisitions (M&A): Mergers and acquisitions are a crucial component of Option Care Health's expansion strategy. The company is actively exploring strategic M&A opportunities to bolster future growth, diversify its revenue streams, and increase market share in the healthcare services sector.
  4. Deepening Partnerships with Payers and Pharmaceutical Manufacturers: Option Care Health emphasizes deepening its partnerships with key stakeholders, including payers and pharmaceutical manufacturers. These collaborations are essential for accessing new customers, adapting to industry changes, securing favorable reimbursement rates, and supporting new drug launches and patient support programs. The company added five new regional health plan programs and two with non-traditional payers in 2025.
  5. Technology Investments and Operational Efficiency: The company is investing in technology, particularly in artificial intelligence (AI) and robotic process automation, to enhance patient onboarding and benefits verification. These efficiency initiatives have already shown positive impacts, with approximately 40% of claims being processed without human intervention.

AI Analysis | Feedback

Share Repurchases

  • Option Care Health repurchased $307 million of shares in fiscal year 2025.
  • From 2021 to the third quarter of 2025, the company repurchased a total of $715 million in shares.
  • The board of directors expanded the share repurchase authorization by an additional $500 million, bringing the total authorization to $1.0 billion.

Share Issuance

  • An affiliate of Walgreens Boots Alliance, Inc. sold 11,000,000 shares of Option Care Health common stock in August 2022.
  • In March 2021, there was a secondary offering of 12,000,000 shares of common stock.

Outbound Investments

  • Option Care Health acquired Intramed Plus in 2025.
  • Strategic acquisitions ("M&A for strategic acquisitions" and "Strategic tuck-ins and near-adjacency acquisitions") are a stated capital allocation priority.

Capital Expenditures

  • Option Care Health deployed $166 million for capital expenditures from 2021 to Q3 2025.
  • The company's capital allocation priorities include organic investment in the business, such as opening new infusion suites and pharmacies, expanding its formulary, and investing in technology like AI for claims processing.
  • Capital expenditures are described as modest.

Better Bets vs. Option Care Health (OPCH)

Latest Trefis Analyses

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

OPCHCVSUNHAVAHADUSMedian
NameOption C.CVS Heal.UnitedHe.Aveanna .Addus Ho. 
Mkt Price31.5880.24334.9011.01123.5080.24
Mkt Cap4.7102.9300.42.42.34.7
Rev LTM5,752420,614449,6622,6761,5025,752
Op Inc LTM33815,06123,924314155338
FCF LTM28215,56722,826198144282
FCF 3Y Avg2657,84917,76597122265
CFO LTM32218,70826,195207152322
CFO 3Y Avg30610,80921,265104130306

Growth & Margins

OPCHCVSUNHAVAHADUSMedian
NameOption C.CVS Heal.UnitedHe.Aveanna .Addus Ho. 
Rev Chg LTM4.0%6.7%3.3%16.8%11.5%6.7%
Rev Chg 3Y Avg11.1%6.5%7.7%12.8%13.5%11.1%
Rev Chg Q4.1%5.4%-0.4%11.8%7.0%5.4%
QoQ Delta Rev Chg LTM1.0%1.3%-0.1%2.8%1.7%1.3%
Op Inc Chg LTM1.5%41.4%-9.2%33.5%25.8%25.8%
Op Inc Chg 3Y Avg4.3%4.1%-8.4%56.3%22.8%4.3%
Op Mgn LTM5.9%3.6%5.3%11.7%10.3%5.9%
Op Mgn 3Y Avg6.2%3.1%6.5%9.4%9.5%6.5%
QoQ Delta Op Mgn LTM0.0%0.2%0.5%0.9%0.3%0.3%
CFO/Rev LTM5.6%4.4%5.8%7.7%10.1%5.8%
CFO/Rev 3Y Avg5.8%2.7%5.0%4.2%9.9%5.0%
FCF/Rev LTM4.9%3.7%5.1%7.4%9.6%5.1%
FCF/Rev 3Y Avg5.0%1.9%4.1%3.8%9.3%4.1%

Valuation

OPCHCVSUNHAVAHADUSMedian
NameOption C.CVS Heal.UnitedHe.Aveanna .Addus Ho. 
Mkt Cap4.7102.9300.42.42.34.7
P/S0.80.20.70.91.50.8
P/Op Inc14.06.812.67.714.612.6
P/EBIT13.66.812.77.514.412.7
P/E22.09.318.97.820.418.9
P/CFO14.75.511.511.614.911.6
Total Yield4.5%14.0%7.9%12.7%5.0%7.9%
Dividend Yield0.0%3.3%2.7%0.0%0.0%0.0%
FCF Yield 3Y Avg6.3%7.6%5.0%4.2%5.7%5.7%
D/E0.30.70.20.60.00.3
Net D/E0.20.60.20.6-0.00.2

Returns

OPCHCVSUNHAVAHADUSMedian
NameOption C.CVS Heal.UnitedHe.Aveanna .Addus Ho. 
1M Rtn0.9%-13.5%-19.7%-15.3%4.7%-13.5%
3M Rtn33.2%-13.1%-13.6%-16.4%2.2%-13.1%
6M Rtn50.9%-12.8%-12.8%50.1%33.3%33.3%
12M Rtn12.0%8.8%10.4%32.6%12.2%12.0%
3Y Rtn5.5%32.0%-33.9%404.8%41.4%32.0%
1M Excs Rtn4.1%-11.9%-18.0%-14.2%3.9%-11.9%
3M Excs Rtn36.5%-11.1%-12.5%-16.6%5.3%-11.1%
6M Excs Rtn51.6%-12.1%-12.0%50.9%34.1%34.1%
12M Excs Rtn2.1%-3.5%-0.3%18.6%1.5%1.5%
3Y Excs Rtn-57.5%-34.3%-97.5%413.0%-22.1%-34.3%

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Infusion Services5,5564,9124,2233,8693,439
Other revenue94878076 
Total5,6504,9984,3023,9453,439


Operating Income by Segment
$ Mil20092008200720062005
Traditional Pharmacy Services17    
Specialty Pharmacy Services-1    
PBM Services 11113-15
Specialty Services -94-2-20-14
Total15-849-16-29


Net Income by Segment
$ Mil202520242023
Infusion Services208212267
Total208212267


Assets by Segment
$ Mil20142013201220112010
Infusion Services756794439  
Corporate unallocated4053962376
PBM Services292536  
Home Health Services 6462  
Infusion/Home Health Services   420442
Pharmacy Services   234146
Total825937633677664


Price Behavior

null
OPCH Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta2.001.201.01-0.210.010.38
Up Beta6.26-1.94-0.47-0.60-0.160.16
Down Beta0.22-0.14-0.03-0.720.050.21
Up Capture642%345%255%52%8%25%
Bmk +ve Days12182862130427
Stock +ve Days15223165120373
Down Capture-27%36%50%-87%-19%85%
Bmk -ve Days10253664121325
Stock -ve Days4183058127370

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with OPCH
OPCH13.8%51.7%0.41-
Sector ETF (XLV)18.4%17.1%0.809.6%
Equity (SPY)5.2%14.4%0.110.4%
Gold (GLD)-13.9%29.3%-0.52-3.6%
Commodities (DBC)28.2%21.5%1.05-6.5%
Real Estate (VNQ)8.6%14.3%0.3313.6%
Bitcoin (BTCUSD)-35.8%43.9%-0.89-0.7%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with OPCH
OPCH3.4%236.9%0.81-
Sector ETF (XLV)7.5%15.4%0.292.4%
Equity (SPY)9.6%17.4%0.391.4%
Gold (GLD)13.1%19.3%0.53-2.5%
Commodities (DBC)6.6%19.6%0.22-3.2%
Real Estate (VNQ)0.5%19.0%-0.08-0.8%
Bitcoin (BTCUSD)-1.7%51.5%0.159.7%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with OPCH
OPCH19.9%173.5%0.70-
Sector ETF (XLV)11.4%16.8%0.558.0%
Equity (SPY)14.1%18.1%0.667.5%
Gold (GLD)10.4%16.6%0.50-1.9%
Commodities (DBC)7.2%18.2%0.31-0.0%
Real Estate (VNQ)5.9%20.7%0.245.6%
Bitcoin (BTCUSD)55.4%66.3%0.956.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity6.1 Mil
Short Interest: % Change Since 10152026-13.7%
Average Daily Volume3.4 Mil
Days-to-Cover Short Interest1.8 days
Basic Shares Quantity149.8 Mil
Short % of Basic Shares4.1%

Earnings Returns History

Updated 11/13/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/4/2026-0.4%-0.4% 
7/29/20266.5%5.4%6.9%
4/30/2026-24.3%-23.9%-22.3%
2/24/2026-6.3%-12.4%-21.3%
10/30/2025-8.6%-5.5%7.9%
7/30/20251.7%-6.7%-5.1%
4/29/2025-6.9%-0.5%-3.7%
2/26/20251.6%4.6%7.4%
...
SUMMARY STATS   
# Positive121012
# Negative131512
Median Positive5.2%7.5%7.3%
Median Negative-6.9%-6.7%-10.2%
Max Positive147.9%157.3%169.6%
Max Negative-24.3%-26.8%-22.3%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/4/2026-0.4%-0.4% 
7/29/20266.5%5.4%6.9%
4/30/2026-24.3%-23.9%-22.3%
2/24/2026-6.3%-12.4%-21.3%
10/30/2025-8.6%-5.5%7.9%
7/30/20251.7%-6.7%-5.1%
4/29/2025-6.9%-0.5%-3.7%
2/26/20251.6%4.6%7.4%
10/30/2024-22.8%-26.8%-22.1%
7/31/2024-5.3%-5.0%0.3%
4/23/20240.6%-0.5%-4.2%
2/22/2024-2.4%-5.2%-2.9%
10/25/2023-15.5%-15.6%-8.2%
7/27/20234.4%3.7%7.2%
5/3/2023-16.1%-17.7%-12.9%
2/23/202310.5%8.4%7.4%
10/27/2022-12.1%-14.2%-17.6%
7/27/20222.6%8.3%1.1%
4/28/202212.5%10.1%7.3%
2/23/2022147.9%157.3%169.6%
11/4/2021-1.8%-3.8%-12.1%
8/3/20214.5%6.6%31.3%
5/6/2021-4.5%-7.9%2.3%
3/11/20215.8%1.3%-3.8%
11/3/20208.4%11.9%14.1%
SUMMARY STATS   
# Positive121012
# Negative131512
Median Positive5.2%7.5%7.3%
Median Negative-6.9%-6.7%-10.2%
Max Positive147.9%157.3%169.6%
Max Negative-24.3%-26.8%-22.3%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/04/202610-Q
06/30/202607/29/202610-Q
03/31/202604/30/202610-Q
12/31/202502/24/202610-K
09/30/202510/30/202510-Q
06/30/202507/30/202510-Q
03/31/202504/29/202510-Q
12/31/202402/26/202510-K
09/30/202410/30/202410-Q
06/30/202407/31/202410-Q
03/31/202404/23/202410-Q
12/31/202302/22/202410-K
09/30/202310/25/202310-Q
06/30/202307/27/202310-Q
03/31/202305/04/202310-Q
12/31/202202/23/202310-K
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/04/202610-Q
06/30/202607/29/202610-Q
03/31/202604/30/202610-Q
12/31/202502/24/202610-K
09/30/202510/30/202510-Q
06/30/202507/30/202510-Q
03/31/202504/29/202510-Q
12/31/202402/26/202510-K
09/30/202410/30/202410-Q
06/30/202407/31/202410-Q
03/31/202404/23/202410-Q
12/31/202302/22/202410-K
09/30/202310/25/202310-Q
06/30/202307/27/202310-Q
03/31/202305/04/202310-Q
12/31/202202/23/202310-K
09/30/202210/27/202210-Q
06/30/202207/27/202210-Q
03/31/202204/28/202210-Q
12/31/202102/23/202210-K
09/30/202111/04/202110-Q
06/30/202108/03/202110-Q
03/31/202105/06/202110-Q
12/31/202003/11/202110-K
09/30/202011/03/202010-Q
06/30/202008/04/202010-Q
03/31/202005/07/202010-Q
12/31/201903/05/202010-K

Insider Activity

Updated 11/12/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Pate, R Carter DirectSell1112202631.6540012,660447,151Form
2Pate, R Carter DirectSell1112202631.656,092192,812459,811Form
3Sullivan, Timothy P DirectBuy507202620.6924,154499,6711,518,067Form
4Sethna, MeenalChief Financial OfficerDirectBuy504202620.1616,225327,0751,982,346Form
5Rademacher, John CharlesChief Executive OfficerDirectBuy504202621.1812,500264,70614,720,886Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Pate, R Carter DirectSell1112202631.6540012,660447,151Form
2Pate, R Carter DirectSell1112202631.656,092192,812459,811Form
3Sullivan, Timothy P DirectBuy507202620.6924,154499,6711,518,067Form
4Sethna, MeenalChief Financial OfficerDirectBuy504202620.1616,225327,0751,982,346Form
5Rademacher, John CharlesChief Executive OfficerDirectBuy504202621.1812,500264,70614,720,886Form
6Pate, R Carter DirectSell303202632.0530,287970,620372,487Form
7Bavaro, MichaelChief Human Resources OfficerDirectSell303202633.006,000198,0001,097,217Form
8Kraemer, Harry M Jansen JR DirectBuy1104202525.9838,000987,39210,741,526Form

Investor Activity (13F)

Updated Nov 22, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Arvin Capital Management LP$18.8 Mil4.4%23ADD +43.2%13F
Durable Capital Partners LP$242.0 Mil2.5%37Hold13F
Southpoint Capital Advisors LP$96.9 Mil2.0%41ADD +20.0%13F
Park West Asset Management LLC$11.4 Mil1.0%48ADD +19.5%13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Arvin Capital Management LP$18.8 Mil4.4%23ADD +43.2%13F
Southpoint Capital Advisors LP$96.9 Mil2.0%41ADD +20.0%13F
Park West Asset Management LLC$11.4 Mil1.0%48ADD +19.5%13F
Active Manager
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Durable Capital Partners LP$242.0 Mil2.5%37Hold13F
Southpoint Capital Advisors LP$96.9 Mil2.0%41ADD +20.0%13F
Arvin Capital Management LP$18.8 Mil4.4%23ADD +43.2%13F
Park West Asset Management LLC$11.4 Mil1.0%48ADD +19.5%13F
Core Cache Last Updated: 11/21/2026